189 related articles for article (PubMed ID: 31666714)
1. Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study.
Clemens E; Broer L; Langer T; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Byrne J; Broeder EVD; Crocco M; Grabow D; Kaatsch P; Kaiser M; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Kuehni CE; van der Pal H; Parfitt R; Deuster D; Matulat P; Spix C; Tillmanns A; Tissing WJE; Maier L; Am Zehnhoff-Dinnesen A; Zolk O; van den Heuvel-Eibrink MM;
Pharmacogenomics J; 2020 Apr; 20(2):294-305. PubMed ID: 31666714
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study.
Langer T; Clemens E; Broer L; Maier L; Uitterlinden AG; de Vries ACH; van Grotel M; Pluijm SFM; Binder H; Mayer B; von dem Knesebeck A; Byrne J; van Dulmen-den Broeder E; Crocco M; Grabow D; Kaatsch P; Kaiser M; Spix C; Kenborg L; Winther JF; Rechnitzer C; Hasle H; Kepak T; van der Kooi AF; Kremer LC; Kruseova J; Bielack S; Sorg B; Hecker-Nolting S; Kuehni CE; Ansari M; Kompis M; van der Pal H; Parfitt R; Deuster D; Matulat P; Tillmanns A; Tissing WJE; Beck JD; Elsner S; Am Zehnhoff-Dinnesen A; van den Heuvel-Eibrink MM; Zolk O;
Eur J Cancer; 2020 Oct; 138():212-224. PubMed ID: 32905960
[TBL] [Abstract][Full Text] [Related]
3. TPMT, COMT and ACYP2 genetic variants in paediatric cancer patients with cisplatin-induced ototoxicity.
Thiesen S; Yin P; Jorgensen AL; Zhang JE; Manzo V; McEvoy L; Barton C; Picton S; Bailey S; Brock P; Vyas H; Walker D; Makin G; Bandi S; Pizer B; Hawcutt DB; Pirmohamed M
Pharmacogenet Genomics; 2017 Jun; 27(6):213-222. PubMed ID: 28445188
[TBL] [Abstract][Full Text] [Related]
4. Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study.
Clemens E; de Vries AC; Pluijm SF; Am Zehnhoff-Dinnesen A; Tissing WJ; Loonen JJ; van Dulmen-den Broeder E; Bresters D; Versluys B; Kremer LC; van der Pal HJ; van Grotel M; van den Heuvel-Eibrink MM;
Eur J Cancer; 2016 Dec; 69():77-85. PubMed ID: 27821322
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.
Choeyprasert W; Sawangpanich R; Lertsukprasert K; Udomsubpayakul U; Songdej D; Unurathapan U; Pakakasama S; Hongeng S
J Pediatr Hematol Oncol; 2013 May; 35(4):e138-43. PubMed ID: 23274376
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin ototoxicity in children: risk factors and its relationship with polymorphisms of DNA repair genes ERCC1, ERCC2, and XRCC1.
Turan C; Kantar M; Aktan Ç; Kosova B; Orman M; Bilgen C; Kirazlı T
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1333-1338. PubMed ID: 31586226
[TBL] [Abstract][Full Text] [Related]
7. Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.
Vos HI; Guchelaar HJ; Gelderblom H; de Bont ES; Kremer LC; Naber AM; Hakobjan MH; van der Graaf WT; Coenen MJ; te Loo DM
Pharmacogenet Genomics; 2016 May; 26(5):243-7. PubMed ID: 26928270
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients.
Yancey A; Harris MS; Egbelakin A; Gilbert J; Pisoni DB; Renbarger J
Pediatr Blood Cancer; 2012 Jul; 59(1):144-8. PubMed ID: 22431292
[TBL] [Abstract][Full Text] [Related]
9. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
10. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and risk factors for cisplatin-induced hearing loss in children, adolescents, and young adults: a multi-institutional North American cohort study.
Moke DJ; Luo C; Millstein J; Knight KR; Rassekh SR; Brooks B; Ross CJD; Wright M; Mena V; Rushing T; Esbenshade AJ; Carleton BC; Orgel E
Lancet Child Adolesc Health; 2021 Apr; 5(4):274-283. PubMed ID: 33581749
[TBL] [Abstract][Full Text] [Related]
12. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.
Xu H; Robinson GW; Huang J; Lim JY; Zhang H; Bass JK; Broniscer A; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Fisher M; Cohn R; Yamashita T; Teitz T; Zuo J; Onar-Thomas A; Gajjar A; Stewart CF; Yang JJ
Nat Genet; 2015 Mar; 47(3):263-6. PubMed ID: 25665007
[TBL] [Abstract][Full Text] [Related]
13. Further Investigation of the Role of
Drögemöller BI; Brooks B; Critchley C; Monzon JG; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Hayden MR; Gelmon KA; Carleton BC; Ross CJD
Clin Cancer Res; 2018 Apr; 24(8):1866-1871. PubMed ID: 29358504
[No Abstract] [Full Text] [Related]
14. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
[TBL] [Abstract][Full Text] [Related]
15. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin-induced hearing loss: the need for a long-term evaluating system.
Yasui N; Adachi N; Kato M; Koh K; Asanuma S; Sakata H; Hanada R
J Pediatr Hematol Oncol; 2014 May; 36(4):e241-5. PubMed ID: 24072246
[TBL] [Abstract][Full Text] [Related]
17. Ototoxicity and long-term hearing outcome in pediatric patients receiving cisplatin.
Sriyapai T; Thongyai K; Phuakpet K; Vathana N; Buaboonnam J; Sanpakit K
Turk J Pediatr; 2022; 64(3):531-541. PubMed ID: 35899566
[TBL] [Abstract][Full Text] [Related]
18. Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.
Spracklen TF; Vorster AA; Ramma L; Dalvie S; Ramesar RS
Pharmacogenomics J; 2017 Dec; 17(6):515-520. PubMed ID: 27457817
[TBL] [Abstract][Full Text] [Related]
19. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.
Ross CJ; Katzov-Eckert H; Dubé MP; Brooks B; Rassekh SR; Barhdadi A; Feroz-Zada Y; Visscher H; Brown AM; Rieder MJ; Rogers PC; Phillips MS; Carleton BC; Hayden MR;
Nat Genet; 2009 Dec; 41(12):1345-9. PubMed ID: 19898482
[TBL] [Abstract][Full Text] [Related]
20. The genetic vulnerability to cisplatin ototoxicity: a systematic review.
Tserga E; Nandwani T; Edvall NK; Bulla J; Patel P; Canlon B; Cederroth CR; Baguley DM
Sci Rep; 2019 Mar; 9(1):3455. PubMed ID: 30837596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
